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Diagnosticciated with most reported cases of inherited, degenerative and acquired
mitochondrial disease. Traditional methods of measuring OXPHOS activities in patients provide valuable
clinical information but require ﬁfty to hundreds of milligrams of biopsy tissue samples in order to isolate
mitochondria for analysis. We have worked to develop assays that require less sample and here report novel
immunocapture assays (lateral ﬂow dipstick immunoassays) to determine the activities of complexes I and
IV, which are far and away the most commonly affected complexes in the class of OXPHOS diseases. These
assays are extremely simple to perform, rapid (1–1.5 h) and reproducible with low intra-assay and inter-
assay coefﬁcients of variability (CVs) s (b10%). Importantly, there is no need to purify mitochondria as crude
extracts of whole cells or tissues are suitable samples. Therefore, the assays allow use of samples obtained
non-invasively such as cheek swabs and whole blood, which are not amenable to traditional mitochondrial
puriﬁcation and OXPHOS enzyme analysis. As a ﬁrst step to assess clinical utility of these novel assays, they
were used to screen a panel of cultured ﬁbroblasts derived from patients with isolated deﬁciencies in
complex I or IV caused by identiﬁed genetic defects. All patients (5/5) with isolated complex IV deﬁciencies
were identiﬁed in this population. Similarly, almost all (22/24) patients with isolated complex I deﬁciencies
were identiﬁed. We believe that this assay approach should ﬁnd widespread utility in initial screening of
patients suspected of having mitochondrial disease.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionDefects of the oxidative phosphorylation (OXPHOS) system are the
cause of many different diseases such as Leigh's, MERRF, MELAS, NARP,
and LHON, each individually rare, but with a combined incidence of
about 1:5000 [1–3]. There are 5 large complexes involved in OXPHOS,
namely NADH ubiquinone oxidoreductase or complex I, succinate
ubiquinone oxidoreductase (complex II), ubiquinone cytochrome c
oxidoreductase (complex III), cytochrome c oxidase (complex IV) and
the ATP synthase (complex V). Isolated deﬁciencies in complex I (CI)
are the most common followed by isolated deﬁciencies of complex IV
(CIV) [4–7]. There are also genetic defects in which multiple OXPHOS
complexes including CI and CIV are deﬁcient resulting either from
long deletions in the mtDNA, from point mutations in the several
tRNAs in this genome required for protein synthesis within the
organelle and in nuclear genes involved e.g. in mitochondrial
maintenance and the mtDNA translation machinery.
Both CI and CIV are large multiprotein enzyme complexes
composed of both mtDNA-encoded and nuclear DNA encoded
subunits. Therefore, deﬁcits in amount or enzyme functioning canpaldi@mitosciences.com
ll rights reserved.result not only from mutations or damage to nuclear or mtDNA-
encoded structural proteins, but also from alterations in nuclear DNA-
encoded factors required for proper assembly of these enzyme
complexes. Indeed, it has been reported that most cases of early-
onset, inherited isolated CI and CIV deﬁciencies are caused by defects
in complex-speciﬁc assembly factors and not in complex-speciﬁc
structural proteins [8].
Detection and diagnosis of OXPHOS deﬁciencies has until now
depended on an extensive evaluation of clinical presentation of
patients along with blood and urine chemistry analysis, particularly
for lactic acid levels and alanine and unexpected metabolic inter-
mediates. Also done are activity measurements of the 5 OXPHOS
complexes, usually from large biopsy of muscle or from ﬁbroblasts
taken from the patient and cultured to produce workable amounts for
mitochondrial puriﬁcation. Open biopsy is invasive, particularly in
infants presentingwith potential OXPHOSdisease and requires general
anesthesia [9]. More acceptable would be methods for measuring
OXPHOS activities that do not require mitochondrial isolation and
could be performed on samples obtained by non-invasive means.
We have recently developed a set of assays for determining the
amount and activity of OXPHOS complexes that use monoclonal
antibody immunocapture to isolate each complex for analysis. Several
attributes provide these assays with the potential to be used in
primary screening of patients with suspected OXPHOS deﬁciency. The
Fig. 1. Complex I and IV enzyme activity dipstick assays. (A) Complex I (CI) Activity
dipstick reaction. Immunocaptured CI oxidizes NADH and reduces NBT, which forms a
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extract. Therefore they can be done on samples obtained by much less
invasive means than an open biopsy e.g. cheek swabs, urine sediment
or blood. If a biopsy is necessary, for example because the defect is
localized to muscle, needle biopsy provides sufﬁcient material for
analysis.
As a ﬁrst step to evaluate the utility of these novel methods we
have compared results obtained by the immunocapture assay
approach with the previous gold standard assays obtained using
intact mitochondria. To do this we have taken advantage of an
important resource, a set of ﬁbroblast cell lines from patients with
deﬁned OXPHOS deﬁciencies collected over several years by the team
of excellent clinical investigators at the Nijmegen Centre for
Mitochondrial Disorders, Radboud University Nijmegen Medical
Centre, Netherlands. For each of these cell lines a clinical proﬁle of
the patient is available as well as OXPHOS activities measured
spectrophotometrically on mitochondria isolated from each. We
show that the dipstick assays work well to identify CIV and CI patients
from controls in almost all (27 of 29) patients tested. There are 2
exceptions, which are discussed in detail later.
2. Materials and methods
2.1. Patients
The clinical, biochemical and genetic data from analysis of the
patients' cultured ﬁbroblasts is presented in Table 1. The study group
was composed of 24 patients with isolated complex I deﬁciencies
(values below the lowest control), 5 with isolated complex IV
deﬁciencies (values below the lowest control) and 10 age-matchedTable 1
Patient data information
Patient # Gene Mutation CI activity
(mU/UCOX)
CIV activity
(mU/UCS)
Complex I
1 NDUFS2 P299Q 29 597
2 NDUFS2 S413P 44 2189
3 NDUFS2 R228Q 54 1163
4 NDUFS2 R228Q nd 860
5 NDUFS2 nd 29 958
6 NDUFS2 F84L/E104G 71 650
7 NDUFS4 W97X nd nd
8 NDUFS4 W97X 65 681
9 NDUFS4 R106X 60 nd
10 NDUFS4 R106X 36 860
11 NDUFS4 VPEEH167/VEKSIstop 62 783
12 NDUFS4 K158fs 75 nd
13 NDUFS7 V122M 65 710
14 NDUFS8 P79L/R102H 80 870
15 NDUFS8 R94C 16 704
16 NDUFV1 R59X/T423M 70 1350
17 NDUFV1 A341V 50 1100
18 NDUFV1 A211V nd nd
19 NDUFV1 R59X/T423M 80 800
20 ND2 L71P 42 920
21 ND3 10191TNC 59 927
22 ND6 M63V 67 924
23 ND5 13513GNA 93 1174
24 ND5 13513GNA 78 1154
Complex IV
25 SURF1 121 117
26 SURF1 G124R nd b62
27 SURF1 INS470A 243 144
28 SURF1 326insATdelTCTGCCAGCC 133 104
29 COX10 M1T 169 220
Controls
Mean 140 (n=10) 805 (n=6)
Range 114–190 620–1077
nd=not determined.
colored precipitate at the complex I immunocapture zone. The signal intensity is
proportional to the concentration of enzymatically active complex I in the sample. (B)
Complex IV (CIV) Activity dipstick reaction. Immunocaptured CIV oxidizes cytochrome
c, which subsequently oxidizes DAB to form a colored precipitate at the complex IV
immunocapture zone. The signal intensity is proportional to the concentration of
enzymatically active CIV in the sample. (C) Representative images of CI activity dipsticks
run (in duplicate) using samples taken from control ﬁbroblasts (C) and patients with
either partial (P6) or complete (P15) reduction in CI activity.controls. Complex I and IV activities were measured as previously
described [10,11].
2.2. Whole cell protein extract preparations
Frozen ﬁbroblasts cell pellets were thawed on ice and washed
three times with 500 μl of PBS (pH 7.4). The cell pellet was then
solubilized in 300 μl of Extraction buffer (1.5% n-Dodecyl-β-D-
maltopyranoside (LM) (Anatrace, Maumee, OH), 25 mM Hepes
(Sigma, St. Louis, MO) 100 mM NaCl (Sigma) with protease inhibitors
(0.5 μg/ml leupeptin, 0.5 μg/ml pepstatin, 1 mM phenylmethylsulfo-
nyl ﬂuoride) for 20 min on ice. Following solubilization, the extract
was clariﬁed by centrifugation at 16,000 rpm for 20 min at 4 °C, the
supernatant saved and stored frozen at −80 °C. Protein concentra-
tions of the solubilized samples were determined by BCA analysis
(Pierce, Rockford Ill.).
2.3. Monoclonal antibodies
Monoclonal antibodies (mAbs) that recognize native complex I
weremade by immunizingmicewith sucrose gradient puriﬁed bovine
heart complex I while anti-complex IV mAbs were made by
immunizing mice with puriﬁed bovine heart mitochondria. The
procedures for hybridoma preparation were as previously described
[12], and the resulting hybridomas were screened for secretion of
mAbs that speciﬁcally immunoprecipitate either complex I (mAb
18G12BC2) or complex IV (mAb 31E91B8) from both human and
bovine heart mitochondria. The resulting immunoprecipitates were
Fig. 2. Both complex I and IV enzyme activity dipsticks accurately measure levels of
enzyme activities in deﬁned blends of wild-type and ρ0 ﬁbroblasts. Blends of wild-type
dermal ﬁbroblast (100% normal levels of both enzymes) and ρ0 dermal ﬁbroblast (0%
normal levels of both enzymes) whole cell extracts were made at precise increments
and dipsticks were then loaded with equivalent amounts of total whole cell protein for
every assay. Both CI (A) and CIV (B) enzyme activity values are nearly directly (1:1)
proportional to the known amounts of assembled functional CI and CIV enzymes in the
mixtures.
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to conﬁrm speciﬁcity for complex I or complex IV [13,14].
The anti-frataxin lateral ﬂow dipstick assays used here have been
previously described [15] and were obtained from MitoSciences, Inc.
2.4. Enzyme activity quantitation dipstick assays
The complex I and IV enzyme activity dipsticks were prepared as
shown in Fig. 1. First, a nitrocellulose membrane (Millipore,
12q×1.25q) was afﬁxed to an adhesive backing card (GL-187, 0.010q
white matte vinyl) followed by placement of a cellulose wicking pad
(Millipore #SA3J441H7) slightly overlapping the membrane. An
Imagene Isoﬂow reagent dispenser (Imagene, Hanover, NH) was
then used to dispense the capture mAbs in narrow zones across the
width of the card. Complex I activity dipsticks contain a zone of anti-
complex I mAb 18G12BC2 striped at 1 mg/ml while the complex IV
activity dipsticks contain a zone of anti-complex IV mAb 31E91B8
stripped at 2 mg/ml (∼18 μl/card). The striped cards were dried for
1 h at 37 °C and then stored in a desiccator chamber. Each card was
then cut into 4 mm wide dipsticks using the Kinematic Matrix 2360
guillotine cutter (Kinematic, Twain Harte, CA).
Dipstick assays were performed by inserting individual dipsticks
into 50 μl samples (25 μl of ﬁbroblast extract mixed with 25 μl of 2×
Sigma Block blocking buffer. The entire sample was then allowed to
wick up laterally through the membrane, passing through the zone
where the target enzymes are immunocaptured and concentrated
(approximately 20 min). The dipsticks were then cleared by allowing
50 μl of wash buffer (50 mM Tris–Cl, 150 mM NaCl, pH 7.4) to wick up
through the dipstick (approximately 15 min). The dipsticks were then
transferred into the appropriate (CI or CIV) enzyme substrate buffer
(described below) and enzyme activities calculated by measuring the
optical density of precipitating, colorimetric enzyme reaction pro-
ducts. A Hamamatsu ICA-1000 immunochromatographic dipstick
reader was used for densitometry.
Complex I activity was revealed and measured by immersing each
complex I activity dipstick in 650 μl of complex I reaction buffer
(20 mM Tris–Cl, pH 7.4 containing 0.1 mg/ml NADH (Sigma) and
0.3 mg/ml Nitrotetrazolium Blue (NBT, BioRad) for 30 min, stopping
the reaction by rinsing with water and then measuring the amount of
intensely colored, reduced NBT, which precipitates at the site of
immunocapture of functional complex I. This functional enzyme assay
for complex I is similar to in-gel activity assays for Complex I activity
used for blue native gels [16,17].
Complex IV activity was measured by immersing each complex IV
activity dipstick in complex IV reaction buffer (50 mM sodium
Phosphate, pH 7.4 containing 0.1 mg/ml 3, 3′-diaminobenzidine
(DAB) and 120 mM reduced cytochrome c (Sigma) for 60 min,
stopping the reaction by rinsing with water and then measuring the
amount of intensely colored, oxidized DAB that precipitates at the site
of immunocaptured functional complex IV. This enzyme assay is
similar to enzyme histochemical assays used to visualize complex IV
activity in tissue sections [18].
2.5. Data analysis
All measurements were performed in duplicate and the results
averaged. The mitochondrial protein frataxin was used to normalize
loading as it has been shown that use of another mitochondrial
protein as a loading control reduces variability of measured OXPHOS
enzyme levels in both controls and patient samples [19].
Standard curves were made for each analyte (complex I activity,
complex IV activity and frataxin protein levels) using a normal human
dermal ﬁbroblast control sample (outside of the control set subse-
quently analyzed) as a reference sample. The concentration of each
analyte in every individual sample (patients and controls) was then
determined by interpolating each raw densitometric dipstick valueinto the appropriate standard curve. The mean value for the study set
of control samples was then calculated, set at 100% for each analyte
and all individual samples were expressed as % of mean for the
appropriate analyte.
3. Results and discussion
3.1. Enzyme activity quantitation dipstick assays measure levels of
functional CI and CIV proteins accurately
The activity dipstick assays described here are lateral ﬂow
immunocapture assays that measure electron transfer activity of
complex I and complex IV proteins. These tests are extremely simple,
rapid (less than 1.5 h), accurate and reproducible. As shown
schematically in Fig. 1, the capture mAb is immobilized in a zone on
a nitrocellulose membrane backed on a plastic support. Samples are
applied to the bottom of the dipstick andwick up laterally through the
immunocapture zone. Target antigens (CI or CIV) in the sample are
thus bound and concentrated in the immunocapture zone. Enzymatic
activity of the captured enzyme is measured by incubating the
Fig. 3. CIV Enzyme activity dipsticks identify all patients with isolated CIV deﬁciencies.
A) 5 of 5 patients with previously identiﬁed deﬁciencies in CIV exhibit CIV dipstick
activity levels below the lowest control value. B) CIV activities measured by dipstick and
traditional methods show a strong positive correlation (R2=0.6779). Patients are
organized by the gene name (see Table 1 for molecular lesion data). Two dipsticks per
sample were analyzed, averaged and the relative levels of CIV activity were interpolated
from a standard curvemade using an independent control sample. Values from patients
were expressed as percent of the control mean (n=6). The range for controls was
40–164% of the control mean, which is shown+/−one standard deviation on the
control bar. All dipstick measurements were normalized to frataxin protein quantity.
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buffer as needed. Enzyme activity dipstick assays thus combine the
speciﬁcity of immunocapture mAbs with the functionality of enzyme
activity assays. The assays incorporate well-established enzyme
activity assays commonly used for both in-gel [16,17], and histoche-
mical [18] assays, using substrates that are both colorimetric and
precipitating (see Materials and methods). The signal generated is
proportional to the amount of active enzyme captured, which is turn is
proportional to the amount of enzyme in the sample as long as
saturating conditions are avoided.
3.2. Enzyme activity dipstick assays are accurate and reproducible
To assess accuracy, reproducibility and potential interference by
other cellular proteins, each assay was tested using a sample set
containing known levels of CI and CIV diluted in a background of
heterogeneous proteins found in total cell extracts. A deﬁned sample
set was made by preparing a graded series of mixtures of wild-type
human skin ﬁbroblasts which contain normal levels of both CI and CIV
(100% normal levels), and ρ0 human skin ﬁbroblasts which com-
pletely lack these complexes (0% of normal). The ρ0 cells were
prepared by growing normal skin ﬁbroblasts in low levels of ethidium
bromide for 10–12 population doublings, which results in complete
depletion mtDNA [20]. Because both CI and CIV require a core of
mtDNA-encoded subunits, ρ0 cells lack any fully assembled CI or CIV.
This was conﬁrmed by western blot and immunocytochemistry (not
shown, but see reference [20]) and by dipstick measurements (Fig. 2).
A strong, direct (1:1) correlation was observed between the
known andmeasured amounts of active enzyme (CIV: R2=0.9956, CI:
R2=0.9913) (Figs. 2A and B) indicating that the assays measure their
target antigens accurately and without interference from other
proteins. In addition, both activity dipstick assays had intra-assay
CVsb10% throughout the working range (n=2).
3.3. CIV enzyme activity dipsticks Identify all CIV patients tested
The sample set consisted of 5 patients with previously identiﬁed
isolated deﬁciencies in CIV based on classical cytochrome c oxidase
measurements that monitor reduction of cytochrome c. As controls, 6
ﬁbroblast cell lines from unaffected individuals were included in the
sample set for CIV analysis. As shown in Fig. 3A, the CIV activity
dipstick assays readily distinguished the CIV patients from the
controls. CIV patient cell lines had dipstick CIV activity values ranging
between 7 and 30% of control mean, while in comparison control cell
line values ranged from 40–164% of the control mean. Consistent with
the positive identiﬁcation of all CIV patients, the individual CIV
activities measured by dipstick and traditional assays are highly
correlated (Fig. 3B).
3.4. CI activity dipsticks identify 22 of 24 CI patients
The CI sample set contained 24 patients with previously identiﬁed
isolateddeﬁciencies in CI. TheCI dipstick activity determination for each
of these 24CIpatients is shown inFig. 4, segregatedby the gene inwhich
the identiﬁed mutation is located, i.e., nuclear genes NDUFS2, NDUFS7,
NDUFS8, NDUFS4, NDUFV1, and themitochondrial encoded subunits. In
all, 22 of the 24 CI patients had residual CI activities below that of the
lowest control (n=10, control range=51–147% of the control mean).
Again, the individual CI activities measured by dipstick and traditional
assays correlate well (Fig. 4B) except for the cases noted below.
Notably, two CI patients had CI dipstick enzyme activities within
the control range and each had a mutation in the mitochondrial
encoded ND5 gene (Fig. 4). Thus, the NADH-NBT reductase dipstick
assay failed to identify 2 patients with 13513 GNA mutations in ND5
although both cell lines had signiﬁcantly reduced NADH-ubiquinone
reductase activities as measured by the classical CI activity assay. ND5is an intrinsic membrane protein located in the core of the complex
but thought not to be involved in ubiquinone binding and is without
an intrinsic prosthetic group (non-heme iron center). However, the
mutation clearly alters electron transfer to or through the ubiquinone
site but evidently does not inhibit electron transfer through the ﬂavin
into the ﬁrst few non-heme iron centers for passage to the electron
acceptor NBT.
3.5. CI and CIV enzyme activity quantitation dipstick assays can be used
to measure levels of CI and CIV in a wide range of clinically-relevant
tissues
Because the enzyme activity dipstick assays are sensitive and do
not require puriﬁcation of mitochondria they can be used to measure
levels of CI and CIV in a variety of clinically important tissue and cell
types (Table 2). Most notable among these are samples collected by
non-invasive means, including buccal swabs (cheek epithelial cells)
and whole blood. A single cheek swab provides sufﬁcient material to
perform more than 100 tests while only microliter samples of whole
blood are needed, amounts obtained easily by ﬁngerprick sampling.
Moreover, the ability to use whole tissue extracts as samples
Fig. 4. CI enzyme activity dipsticks identify almost all (22 of 24) patients with isolated CI deﬁciencies. A) 22 of 24 patients with previously identiﬁed deﬁciencies in CI exhibit CI
dipstick activity levels below the lowest control value. (B) CI activities measured by dipstick and the traditional, rotenone-sensitive assay for CI activity show a positive correlation
(R2=0.494). Patients are grouped by gene name and patient # (see Table 1 for more information). Two dipsticks per sample were analyzed, averaged and the relative levels of CI
activity interpolated from a standard curve made using an independent control sample. Values from patients were expressed as percent of the control mean (n=10). The range for
controls was 51–147% of mean, which is shown+/−one standard deviation on the control bar. All dipstick measurements were normalized to frataxin protein quantity.
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namely the selective puriﬁcation of healthy mitochondria during
mitochondrial isolation procedures needed to prepare tissue samples
for other types of analysis [21].
3.6. Prospects for using immunocapture based assays in diagnosis of
OXPHOS diseases
Traditional OXPHOS enzyme assays provide important clinically-
relevant information regarding mitochondrial function, but areTable 2
Dipstick enzyme activity assay working ranges for various human tissue types
Sample type CI activity CIV activity
Fibroblasts 2–30 μg 2–50 μg
Cheek cells (Buccal) 2–30 μg 2–50 μg
Whole blood 3–30 μl 3–30 μl
PBMC 2–30 μg 2–50 μg
Muscle tissue 0.5–10 μg 1–25 μg
Values shown are the amount of total cell protein or volume of whole blood loaded per
dipstick test.complex and require sophisticated laboratory equipment and skilled
personnel for proper performance. They are also difﬁcult to
standardize, making direct comparison of inter-lab test results
problematic as demonstrated recently in a large comparative study
in which multiple highly competent clinical labs assayed a standar-
dized sample set, generating widely divergent results [22]. In
contrast, the CI and CIV enzyme activity dipstick assays described
here are simple, robust tools, well-suited for use as standardized
diagnostic assays.
As shown above, the assays provide results comparable to
traditional enzyme assays. The CIV dipstick activity assay was able
to identify all 5 of the CIV patients identiﬁed previously by the more
laborious traditional spectrophotometric CIV assay now used routi-
nely as part of the evaluation of OXPHOS diseases. Similarly, although
the CI dipstick activity assay measures only a partial activity, i.e., of
electrons through the ﬂavin and non-heme iron prothetic groups into
NBT as an electron acceptor instead of passage through the entire
complex and into ubiquinone, this simple assay identiﬁed 22 of 24
patients previously identiﬁed as CI deﬁcient by the traditional
ubiquinone reductase CI activity assay. Therefore, together the CI
and CIV assays accurately detected 27 out of the 29 cases tested of a
538 J.H. Willis et al. / Biochimica et Biophysica Acta 1787 (2009) 533–538previously identiﬁed OXPHOS deﬁciency, or approximately 93%
accuracy in comparison to the standard methods.
We have not considered the detection of mutations in complexes II,
III or V in the present study, as they have been shown to account for
only a small fraction of the OXPHOS defects identiﬁed to date, perhaps
5%. Taking these into account, together our dipstick assays for complex
I and IV can be predicted to detect approximately 90% of all cases of
OXPHOS enzyme deﬁcits currently detectable by individual OXPHOS
enzyme assays (93% accuracy of the 95% CI/CIV patients among the
total). Given that the dipstick assays are so easy to perform, are
reliable and require minimal amounts of sample, allowing measure-
ment of CI and CIV activities in whole tissue extracts of non-invasive
tissue samples such as buccal (cheek) swabs and whole blood, there is
reason to believe that these two assays could be employed in an initial
point of care screen that would be very valuable in diagnosis and
management of patients. Although there is only limited data on the
extent to which OXPHOS diseases are expressed in these easily
accessible tissues, several recent studies indicate that OXPHOS
abnormalities are reliably detected in them, with buccal samples
being the more reliable sample when mtDNA mutation loads in each
tissue are compared to those in skeletal muscle [23–25]. Further work
is merited to assess the clinical utility of enzyme activity dipstick
assays to detect OXPHOS deﬁcits in patients using these tissues.
Recent clinical evaluation of a similar set of dipstick assays that
measure the quantity (not activity) of assembled CI and CIV further
demonstrates the promise of this approach [26]. In a study of the
adverse metabolic effects of anti-HIV/AIDS drug therapy, we demon-
strated that levels of assembled CI and CIV in peripheral blood
mononucleated cells (PBMCs) parallel changes of CI and CIV levels in
fat (a clinically affected tissue). Dipstick measurement of CI and/or
CIV levels in easily sampled PBMCs could therefore serve as surrogate
markers for OXPHOS deﬁcits in peripheral fat which is itself only
accessible by open biopsy [26].References
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